Home > Neurology > EAN 2020 > Epilepsy > Prevalence of autoantibodies in epilepsy almost 10%

Prevalence of autoantibodies in epilepsy almost 10%

Presented By
Dr Ronan McGinty, University of Oxford, UK
Conference
EAN 2020
At clinics in the UK, 9.3% of epilepsy outpatients had potentially pathogenic autoantibodies. The proportion of antibody-positive patients was similar across patients with new-onset focal epilepsy, drug-resistant epilepsy, and seizure-free epilepsy. The prevalence of autoantibodies among people with epilepsy is not clear; rates between 5-80% have previously been reported. By determining the prevalence of largely pathogenic antibodies in prospectively recruited outpatients with new-onset focal epilepsy, drug-resistant epilepsy, and seizure-free epilepsy, British researchers aimed to provide a prevalence rate that is generalisable to the broader population of epilepsy patients [1]. They screened collected serum on live cell-based assays for neuronal-surface antibodies (NSAs) to LGI1, CASPR2, contactin-2, DPPX, antibodies to intracellular GAD65, and the GABAA, GABAB, glycine, and NMDA receptors. Overall, autoantibodies were detected in 5...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on